Natural D -glucose as a biodegradable MRI contrast agent for detecting cancer

Research output: Contribution to journalArticle

Abstract

Purpose: Modern imaging technologies such as CT, PET, SPECT, and MRI employ contrast agents to visualize the tumor microenvironment, providing information on malignancy and response to treatment. Currently, all clinical imaging agents require chemical labeling, i.e. with iodine (CT), radioisotopes (PET/SPECT), or paramagnetic metals (MRI). The goal was to explore the possibility of using simple D-glucose as an infusable biodegradable MRI agent for cancer detection. Methods: D-glucose signals were detected using chemical exchange saturation transfer (glucoCEST) MRI of its hydroxyl groups. Feasibility was established in phantoms as well as in vivo using two human breast cancer cell lines, MDA-MB-231 and MCF-7, implanted orthotopically in nude mice. PET and contrast-enhanced MRI were also acquired. Results: Both tumor types exhibited significant glucoCEST signal enhancement during systemic sugar infusion (mild hyperglycemia), allowing their noninvasive visualization. GlucoCEST showed differences between types, while PET and CE-MRI did not. Data are discussed in terms of signal contributions from the increased vascular volume in tumors and especially from the acidic extracellular extravascular space (EES), where glucoCEST signal is expected to be enhanced due to a slow down of hydroxyl proton exchange. Conclusions: This observation opens up the possibility for using simple non-toxic sugars as contrast agents for cancer detection with MRI by employing hydroxyl protons as a natural label.

Original languageEnglish (US)
Pages (from-to)1764-1773
Number of pages10
JournalMagnetic Resonance in Medicine
Volume68
Issue number6
DOIs
StatePublished - Dec 2012

Fingerprint

Contrast Media
Hydroxyl Radical
Glucose
Iodine Radioisotopes
Protons
Neoplasms
Tumor Microenvironment
Extracellular Space
Single-Photon Emission-Computed Tomography
Tumor Burden
Nude Mice
Hyperglycemia
Blood Vessels
Metals
Breast Neoplasms
Technology
Cell Line

Keywords

  • biodegradable; glucoCEST
  • cancer detection
  • contrast agent
  • glucose
  • MRI
  • screening

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

@article{9e91746677194dd79deb2119e50c575c,
title = "Natural D -glucose as a biodegradable MRI contrast agent for detecting cancer",
abstract = "Purpose: Modern imaging technologies such as CT, PET, SPECT, and MRI employ contrast agents to visualize the tumor microenvironment, providing information on malignancy and response to treatment. Currently, all clinical imaging agents require chemical labeling, i.e. with iodine (CT), radioisotopes (PET/SPECT), or paramagnetic metals (MRI). The goal was to explore the possibility of using simple D-glucose as an infusable biodegradable MRI agent for cancer detection. Methods: D-glucose signals were detected using chemical exchange saturation transfer (glucoCEST) MRI of its hydroxyl groups. Feasibility was established in phantoms as well as in vivo using two human breast cancer cell lines, MDA-MB-231 and MCF-7, implanted orthotopically in nude mice. PET and contrast-enhanced MRI were also acquired. Results: Both tumor types exhibited significant glucoCEST signal enhancement during systemic sugar infusion (mild hyperglycemia), allowing their noninvasive visualization. GlucoCEST showed differences between types, while PET and CE-MRI did not. Data are discussed in terms of signal contributions from the increased vascular volume in tumors and especially from the acidic extracellular extravascular space (EES), where glucoCEST signal is expected to be enhanced due to a slow down of hydroxyl proton exchange. Conclusions: This observation opens up the possibility for using simple non-toxic sugars as contrast agents for cancer detection with MRI by employing hydroxyl protons as a natural label.",
keywords = "biodegradable; glucoCEST, cancer detection, contrast agent, glucose, MRI, screening",
author = "Chan, {Kannie W Y} and Mcmahon, {Michael T} and Yoshinori Kato and Guanshu Liu and Bulte, {Jeff W} and Bhujwalla, {Zaver M} and Dmitri Artemov and {Van Zijl}, {Peter C}",
year = "2012",
month = "12",
doi = "10.1002/mrm.24520",
language = "English (US)",
volume = "68",
pages = "1764--1773",
journal = "Magnetic Resonance in Medicine",
issn = "0740-3194",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Natural D -glucose as a biodegradable MRI contrast agent for detecting cancer

AU - Chan, Kannie W Y

AU - Mcmahon, Michael T

AU - Kato, Yoshinori

AU - Liu, Guanshu

AU - Bulte, Jeff W

AU - Bhujwalla, Zaver M

AU - Artemov, Dmitri

AU - Van Zijl, Peter C

PY - 2012/12

Y1 - 2012/12

N2 - Purpose: Modern imaging technologies such as CT, PET, SPECT, and MRI employ contrast agents to visualize the tumor microenvironment, providing information on malignancy and response to treatment. Currently, all clinical imaging agents require chemical labeling, i.e. with iodine (CT), radioisotopes (PET/SPECT), or paramagnetic metals (MRI). The goal was to explore the possibility of using simple D-glucose as an infusable biodegradable MRI agent for cancer detection. Methods: D-glucose signals were detected using chemical exchange saturation transfer (glucoCEST) MRI of its hydroxyl groups. Feasibility was established in phantoms as well as in vivo using two human breast cancer cell lines, MDA-MB-231 and MCF-7, implanted orthotopically in nude mice. PET and contrast-enhanced MRI were also acquired. Results: Both tumor types exhibited significant glucoCEST signal enhancement during systemic sugar infusion (mild hyperglycemia), allowing their noninvasive visualization. GlucoCEST showed differences between types, while PET and CE-MRI did not. Data are discussed in terms of signal contributions from the increased vascular volume in tumors and especially from the acidic extracellular extravascular space (EES), where glucoCEST signal is expected to be enhanced due to a slow down of hydroxyl proton exchange. Conclusions: This observation opens up the possibility for using simple non-toxic sugars as contrast agents for cancer detection with MRI by employing hydroxyl protons as a natural label.

AB - Purpose: Modern imaging technologies such as CT, PET, SPECT, and MRI employ contrast agents to visualize the tumor microenvironment, providing information on malignancy and response to treatment. Currently, all clinical imaging agents require chemical labeling, i.e. with iodine (CT), radioisotopes (PET/SPECT), or paramagnetic metals (MRI). The goal was to explore the possibility of using simple D-glucose as an infusable biodegradable MRI agent for cancer detection. Methods: D-glucose signals were detected using chemical exchange saturation transfer (glucoCEST) MRI of its hydroxyl groups. Feasibility was established in phantoms as well as in vivo using two human breast cancer cell lines, MDA-MB-231 and MCF-7, implanted orthotopically in nude mice. PET and contrast-enhanced MRI were also acquired. Results: Both tumor types exhibited significant glucoCEST signal enhancement during systemic sugar infusion (mild hyperglycemia), allowing their noninvasive visualization. GlucoCEST showed differences between types, while PET and CE-MRI did not. Data are discussed in terms of signal contributions from the increased vascular volume in tumors and especially from the acidic extracellular extravascular space (EES), where glucoCEST signal is expected to be enhanced due to a slow down of hydroxyl proton exchange. Conclusions: This observation opens up the possibility for using simple non-toxic sugars as contrast agents for cancer detection with MRI by employing hydroxyl protons as a natural label.

KW - biodegradable; glucoCEST

KW - cancer detection

KW - contrast agent

KW - glucose

KW - MRI

KW - screening

UR - http://www.scopus.com/inward/record.url?scp=84870058718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870058718&partnerID=8YFLogxK

U2 - 10.1002/mrm.24520

DO - 10.1002/mrm.24520

M3 - Article

C2 - 23074027

AN - SCOPUS:84870058718

VL - 68

SP - 1764

EP - 1773

JO - Magnetic Resonance in Medicine

JF - Magnetic Resonance in Medicine

SN - 0740-3194

IS - 6

ER -